Using miRNA encoding necroptosis mediator MLKL to treat melanoma cells not only induces necroptosis but also elicits robust antitumor responses, significantly enhancing tumor growth inhibition when combined with PD-1 inhibitors [189, 190]. The gene discussed is MLKL; the disease is neoplasm.